Ignite Creation Date:
2024-05-05 @ 5:21 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00431496
Status:
COMPLETED
Last Update Posted:
2013-04-24
First Post:
2007-02-01
Brief Title:
A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative KDOQI Targets in Patients With End Stage Renal Disease ESRD
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Study To Assess Achievement of NKF KDOQI Targets Using Sensipar Cinacalcet in Australian Subjects With End Stage Renal Disease ESRD Who Are Being Treated With Aranesp for Anaemia Management
Status:
COMPLETED
Status Verified Date:
2013-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to show that the use of cinacalcet in patients with End Stage Renal Disease can help achieve NKF KDOQI targets for both serum calcium and calcium phosphorous product
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| To Target | None | None | None |